SKYE (Skye Bioscience) Research & Development: $43.10 Mil (TTM As of Mar. 2026)


SKYE Skye Bioscience Inc SKYE
30 GF Score
Price $0.70
! 1 Warning Sign
View Full Analysis

What is Skye Bioscience Research & Development?

Skye Bioscience SKYE +2.41% 30 Research & Development is $43.10 Mil as of Mar. 2026. GuruFocus rates SKYE with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Skye Bioscience's Research & Development for the three months ended in Mar. 2026 was $7.94 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $43.10 Mil.

Skye Bioscience  (NAS:SKYE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Skye Bioscience Research & Development Related Terms

Skye Bioscience Research & Development Historical Data

* Premium members only.

The historical data trend for Skye Bioscience's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skye Bioscience Research & Development Chart

Skye Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.93 6.01 5.82 18.70 42.36

Skye Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.20 14.34 9.36 11.47 7.94
SKYE
30GF Score
Skye Bioscience Inc SKYE
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Skye Bioscience Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $43.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $43.10 Mil mean?
Skye Bioscience (SKYE) has a Research & Development of $43.10 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Skye Bioscience and its competitors.
Is Skye Bioscience's Research & Development too high?
Skye Bioscience's current Research & Development is $43.10 Mil. Overall, Skye Bioscience has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Skye Bioscience's Research & Development compare to PLRZ and NEUP?
Skye Bioscience's Research & Development of $43.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Skye Bioscience and its competitors. Skye Bioscience's current Research & Development is $43.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skye Bioscience stock overvalued right now?
Skye Bioscience (SKYE) has a current Research & Development of $43.10 Mil. The current Research & Development is $43.10 Mil. Skye Bioscience's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Skye Bioscience (SKYE), the current Research & Development is $43.10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Skye Bioscience Business Description

Other Exchanges 09R:Germany
Address 11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
30GF Score

Get the complete analysis for SKYE

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price